Expanding the Neoantigen Strategy Beyond Melanoma: Evolving Target Selection Across Tumor Types to Expand PCV Applicability
Time: 11:30 am
day: Conference Day One
Details:
• Translating lessons from V940 to inform indication expansion and optimize antigen design across tumor types with differing immune responsiveness
• Validating evolving antigen strategies in early-stage settings to accelerate clinical translation and enable faster access
• Navigating regulatory considerations to determine when antigen selection strategy constitutes a new product vs an extension of platform intent
